Biogen Multiple Sclerosis Pregnancy Exposure Registry
Completed
Conditions studied: Multiple Sclerosis, Exposure During Pregnancy
In brief
The primary objective of the study is to prospectively evaluate pregnancy outcomes in women with multiple sclerosis who were exposed to a Registry-specified Biogen Multiple Sclerosis product during the eligibility window for that product. The Registry-specified Biogen MS products being studied are dimethyl fumarate, and Pegylated human interferon beta-1a. The secondary objective of the study is to prospectively evaluate pregnancy outcomes in women with MS who were unexposed to disease-modifying therapies (DMTs).
Key facts
- Study ID
- NCT01911767
- Run by
- Biogen
- People needed
- 408
- Starts
- 2013-10-30
- Expected to finish
- 2022-02-10
- Last updated by the study team
- 2022-06-21
Who can join
Age: any. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Research Site — Cambridge, Massachusetts, United States
- Research Site — Box Hill, Victoria, Australia
- Research Site — Cambridge, Massachusetts, Canada
- Research Site — Bron, Cedex, France
- Research Site — Bochum, Nordrhein Wesfalen, Germany
- Research Site — Dublin, Ireland
- Research Site — Florence, Italy
- Research Site — Genova, Italy
- Research Site — Milan, Italy
- Research Site — Palermo, Italy
- Research Site — Roma, Italy
- Research Site — Bialystok, Poland
- Research Site — Madrid, Spain
- Research Site — Málaga, Spain
- Research Site — Salford, Greater Manchester, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.